1 TITLE

2 Impact of Nasopharyngeal Specimen Quality on SARS-CoV-2 Test Sensitivity

3 ABBREVIATED TITLE

4 Specimen Quality and SARS-CoV-2 Ct

5 **AUTHORS**

- 6 Melissa Richard-Greenblatt, PhD (1); Matthew J. Ziegler, MD, MS (2,3); Valerie Bromberg (2);
- 7 Elizabeth Huang (2); Hatem Abdallah (2); Pam Tolomeo, MS (2); Ebbing Lautenbach, MD,
- 8 MPH, MS (2,3); Laurel Glaser, MD, PhD (1); Brendan J. Kelly, MD, MS (2,3)

9 **AFFILIATIONS**

- 10 1 Department of Pathology and Laboratory Medicine;
- 2 Division of Infectious Diseases, Department of Medicine;
- 12 3 Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine,
- 13 University of Pennsylvania, Philadelphia, PA

14 CORRESPONDING AUTHOR CONTACT

15 Brendan J. Kelly, MD, MS - brendank@pennmedicine.upenn.edu

16 **AUTHORS' CONTRIBUTIONS**

- 17 MRG study design, data collection, manuscript;
- 18 MJZ study design, data analysis, manuscript;
- 19 VB data collection, manuscript;
- 20 EH data collection, manuscript;
- 21 HA data collection, manuscript;
- 22 PT data collection, manuscript;
- 23 EL data analysis; manuscript;

LG - study design, manuscript: BJK - study design, data analysis, manuscript **DISCLOSURES** The authors report no relevant disclosures. **DATA AVAILABILITY** Data, analysis scripts, and model code are available at github.com/bjklab. **KEYWORDS** SARS-CoV-2, cycle of threshold, test sensitivity **Acknowledgements:** BJK, MJZ, and EL are supported in part by a CDC Cooperative Agreement FOA#CK16-004 "Epicenters for the Prevention of Healthcare Associated Infections". BJK is supported by the National Institute for Allergy and Infectious Diseases (K23 Al121485 and L30 Al120149). MJZ is supported by the National Institute for Allergy and Infectious Diseases (K23 Al143925).

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Abstract Background: The SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) cycle of threshold (Ct) has been used to estimate quantitative viral load, with the goal of targeting isolation precautions for individuals with COVID-19 and guiding public health interventions. However, variability in specimen quality can alter the Ct values obtained from SARS-CoV-2 clinical assays. We sought to define how variable nasopharyngeal (NP) swab quality impacts clinical SARS-CoV-2 test sensitivity. **Methods**: We performed amplification of a human gene target (β-actin) in parallel with a clinical RT-PCR targeting the SARS-CoV-2 ORF1ab gene for 1311 NP specimens collected from patients with clinical concern for COVID-19. We evaluated the relationship between NP specimen quality, characterized by high Ct values for the human gene target β-actin Ct, and the probability of SARS-CoV-2 detection via logistic regression, as well as the linear relationship between SARS-CoV-2 and β-actin Ct. Results: Low quality NP swabs are less likely to detect SARS-CoV-2 (odds ratio 0.654, 95%CI 0.523 to 0.802). We observed a positive linear relationship between SARS-CoV-2 and β-actin Ct values (slope 0.169, 95%CI 0.092 to 0.247). COVID-19 disease severity was not associated with β-actin Ct values. Conclusions: Variability in NP specimen quality accounts for significant differences in the sensitivity of clinical SARS-CoV-2 assays. If unrecognized, low quality NP specimens, which are characterized by a low level of amplifiable human DNA target, may limit the application of SARS-CoV-2 Ct values to direct infection control and public health interventions.

Introduction:

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

As the COVID-19 pandemic continues to drive morbidity and mortality around the world, interest has grown in using SARS-CoV-2 reverse-transcription polymerase chain reaction (RT-PCR) cycle of threshold (Ct) values as a means of quantifying viral load (1, 2). It has been proposed that SARS-CoV-2 Ct values may correspond with viral burden and infectivity, and that SARS-CoV-2 values may be used to predict disease severity and guide isolation precautions for individuals with COVID-19 (3-7). SARS-CoV-2 Ct values have been shown to correspond with community COVID-19 burden, and it has also been proposed that community Ct values may help to guide non-pharmaceutical interventions to control COVID-19 (8). We sought to understand the impact of nasopharyngeal (NP) specimen swab quality on the measurement of SARS-CoV-2 Ct and the sensitivity of virus detection. To collect an NP swab for SARS-CoV-2 testing, healthcare workers are instructed to advance a synthetic fiber swab with plastic or wire shaft through the nostril until contacting the posterior nasopharynx at a depth equal to the distance from the nostril to the opening of the ear, then to rub and roll the swab. leaving the swab in place for several seconds to collect secretions, before rotating the swab further as it is removed from the nostril (9). Variability in practice and patient tolerance of the procedure has been observed, and may impact the sensitivity of SARS-CoV-2 detection, as well as the cycle threshold (Ct) value observed when SARS-CoV-2 is detected (10–12). To measure variability in the quality of NP swab collection, we performed amplification of a human gene target (β-actin) in parallel with RT-PCR targeting the SARS-CoV-2 *ORF1ab* gene. High β-actin Ct values have been previously validated as a marker of poor NP swab quality (2. 13). Below we report the relationship between quality of NP swab collection, sensitivity of SARS-CoV-2 detection, and the range of impact we expect sub-standard NP swab collection may exert on SARS-CoV-2 Ct values. We also examine the possibility of confounding by COVID-19 disease severity.

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

Materials and Methods: Study Design, Setting, and Population: We performed a retrospective cohort study, capturing consecutive SARS-CoV-2 RT-PCR tests performed at the Clinical Microbiology Laboratory of the Hospital of the University of Pennsylvania between March 26 and July 4, 2020. We included all SARS-CoV-2 RT-PCR results performed on NP specimens via the BD Max SARS-CoV-2 assay (Becton Dickinson) for which a positive PCR control analyte (MS2 phage DNA) was detected. A total of 1311 NP specimens were included. All specimens were assayed for β-actin and MS2 phage DNA in parallel with SARS-CoV-2. A waiver of informed consent was granted by the University of Pennsylvania Institutional Review Board (IRB protocols #843085 & #843274). **Causal Models**: We hypothesized that β-actin and SARS-CoV-2 Ct values are related because poor NP specimen collection technique results in reduced capture of NP epithelial cells and SARS-CoV-2 alike. β-actin is a commonly used endogenous reference gene, used as an internal control for PCR reactions involving human specimens. This gene has been previously validated as a marker for the presence of nasal epithelial cells, and prior research has supported its use to assess the quality of self-collected midturbinate swabs (2, 13). We additionally considered the possibility of confounding by COVID-19 severity of illness. It is possible that those with more severe infection may have greater NP epithelial cell damage, resulting in greater detection of both PCR targets, irrespective of sampling technique. Clinical Data Collection: To evaluate the possibility of confounding by disease severity, we measured two independent markers of respiratory illness: (1) the minimum room-air oxygen saturation recorded within 2 days of SARS-CoV-2 testing, and (2) whether infiltrates were observed chest computerized tomography (CT) imaging performed within 7 days of SARS-CoV-

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

2 testing. Per Centers for Disease Control and Prevention (CDC) guidelines(14), we considered room-air oxygen saturation < 94% indicative of severe respiratory illness. Radiology reports for CT imaging that described parenchymal lung disease, including "infiltrates", "pneumonia", "groundglass", or other "opacities", were considered indicative of severe respiratory illness. The presence of lung nodules, lung masses, chronic airway disease including bronchiectasis, emphysematous changes, or pleural effusions in the absence of parenchymal disease as described above, were not considered indicative of severe acute respiratory illness. Specimen Collection, Processing, and RT-PCR Assay: Specimens were collected during routine clinical practice using a nylon flocked mini-tip swab collected in VTM or saline. Healthcare providers obtained samples using CDC guidelines for NP samples collection. Samples were transported to the laboratory at ambient temperature and stored at 4°C if not run immediately. Exk TNA2 extraction reagent kits (Becton Dickinson) for the BD MAX open system reagent suite were used for the lab-developed SARS-CoV-2 assay based on a previously described assay (15, 16). The BD MAX system was set to run type 1 workflow. PCR conditions consisted of a reverse transcriptase step (600s at 58°C, 1 cycle), denaturation step (60s at 98°C, 1 cycle) and extension steps (10s at 98°C followed by 40s at 63°C, 40 cycles). Two different sets of primer/probe master mix were prepared and 12.5 µl was aliquoted into BD MAX 0.3 mL snap-in conical tubes for storage at -70°C prior to use. The LUNA Universal Probe One-Step RT-qPCR kit (New England Biolabs) was used to prepare the master mix according to manufacturer guidelines with modified primer and probe concentrations. Master mix 1 was composed of the SARS-CoV-2 orf1ab target (0.6 μM primers and 0.2 μM probe, sequences: unpublished data), and the internal processing control MS2 bacteriophage (0.1 µM primers and probe, sequences) (17). Master mix 2 contained the β-actin primers (0.6 μM) and probe (0.2 µM) (18). Samples were prepared by adding 200µl of NP specimen and 20 µl of specimen processing control (5x106 pfu/mL MS2 Phage; Zeptometrix) to an Exk TNA2 sample buffer

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

tube. Sample buffer tubes containing patient specimens were loaded onto the BD MAX System racks along with the Exk TNA2 test strips. Master mix 1, neutralization buffer (25 µl NucliSENS easyMAG Extraction Buffer 3, Biomerieux) and master mix 2 were snapped in to open positions 2 to 4, respectively, on the test strip prior to loading the rack onto the BD MAX system. All NP samples for which the specimen processing control target (MS2) was detected were included in the study (n=1311). Ct values for all three targets (β-actin, MS2 and SARS-CoV-2) were recorded. **Definition of Exposures and Outcomes**: The primary exposure of interest was the β-actin Ct value, a surrogate for the quality of NP swab collection. The primary outcome of interest was SARS-CoV-2 Ct value. Statistical Methods: Data were organized using R statistical software version 3.6.1 (19), and plots generated using the "ggplot2" package (20). Where β-actin and SARS-CoV-2 were not detected, Ct values were imputed as 40 cycles. We examined (1) the linear relationship between β-actin and SARS-CoV-2 Ct values, as well as (2) the impact of β-actin Ct on SARS-CoV-2 detection using Bayesian linear and generalized-linear mixed effects models, which were fit using Stan Hamiltonian Monte Carlo (HMC) version 2.21, via the "brms" package with default weakly-informative priors (21, 22). Prior predictive modeling was performed, and models were fit with 4 chains of 1000 iterations, confirmed with HMC diagnostics (no divergent iterations, Rhat statistic < 1.1 for all parameters, and E-BFMI > 0.2) (23–25). We examined parameter distributions at 50%, 80%, and 95% posterior credible intervals to understand the relationship between exposure and outcome variables. Power and Sample Size: We estimated the necessary cohort size based on the anticipated effect of poor NP swab quantity (26). We anticipated that approximately 800 subjects would detect a 10% reduction in sensitivity of SARS-CoV-2 detection related to a β-actin Ct increase of 10, with credible intervals precision ensuring type S error < 5% (27, 28). We targeted enrollment

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

of 10% more subjects to allow for a margin of error in that estimate, and we exceeded our enrollment target. Availability of Data: Data, analysis scripts, and model code are available at github.com/bjklab. Results: SARS-CoV-2 Detection and Cycle of Threshold Range: Of 1311 tested specimens, 138 were found to have detectable SARS-CoV-2 within 40 cycles of PCR. Among these specimens, median SARS-CoV-2 Ct was 28.15 (IQR 20.5 to 32.98). No secular trend was observed between calendar time from local onset of COVID-19 cases and SARS-CoV-2 Ct values during the study period (Pearson correlation 0.18). Figure 1 depicts the distribution of SARS-CoV-2 Ct values. Relationship between β-Actin and SARS-CoV-2 Cycle of Threshold: We evaluated the relationship between NP specimen quality, meaured by β-actin Ct value, and SARS-CoV-2 test sensitivity with logistic regression, and we found that increasing β-actin is significantly associated with reduced detection of SARS-CoV-2 (odds ratio 0.654, 95%CI 0.523 to 0.802). Figure 2 depicts the relationship between β-actin and SARS-CoV-2 detection probability. We further evaluated the linear relationship between β-actin and SARS-CoV-2 Ct values with linear regression, and we found that SARS-CoV-2 Ct increases significantly with β-actin Ct (slope 0.169, 95%CI 0.092 to 0.247). A linear model restricted to include only the 134 specimens within which both SARS-CoV-2 and β-actin were detectable (i.e., Ct < 40) also found that SARS-CoV-2 Ct increased with β-actin, but this relationship did not have high posterior certainty (slope 0.254, 95%CI -0.23 to 0.73), and linear model fit was poor. Impact of Poor NP Specimen Quality on SARS-CoV-2 Detection Sensitivity: To understand the potential impact of poor NP specimen quality, we evaluated the change in probability of

SARS-CoV-2 detection as β-actin Ct increases. We found that a 4-Ct increase in β-actin, from Ct of 28 to Ct of 32 (roughly from the first quartile of observed β-actin Ct values to the third quartile) results in a 5.4% (95%CI 2.7% to 8.2%) decreased probability of SARS-CoV-2 detection. Impact of Disease Severity on Relationship Between β-Actin and SARS-CoV-2 Cycle of Threshold: Considering the possibility that the observed association between SARS-CoV-2 and B-actin Ct values is confounded by respiratory illness severity, we evaluated the relationship between β-actin Ct and independent markers of respiratory illness. Oxygen saturation data were available for 428 (32.6%) subjects; chest CT imaging was available for 111 (8.5%) subjects. Linear regression relating β-actin Ct values to oxygen saturation revealed no significant association, and the point estimate of association ran counter to concern for confounding by disease severity. Lower oxygen saturation was in fact associated with higher β-actin Ct values (less β-actin amplicon), with linear regression slope -0.04 (95%Cl -0.273 to 0.182). Similarly, we found that the presence of parenchymal lung disease on chest CT radiography reports had no significant association with β-actin Ct values, and that the point estimate of association actually suggests lung parenchymal infiltrates are associated with higher β -actin Ct values (less β -actin Ct amplicon) with linear regression slope 0.428 (95%CI -0.655 to 1.61). These analyses of independent markers of severe respiratory disease suggest that it is NP specimen quality, not disease severity, that drives the association between SARS-CoV-2 and β -actin Ct values.

Discussion:

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

In this study, we found that higher β-actin Ct values, which have been previously validated as a marker of low NP swab quality (2, 13), were associated with reduced probability of SARS-CoV-2 detection (odds ratio 0.654, 95%CI 0.523 to 0.802) and with higher SARS-CoV-2 Ct values

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

(linear regression slope 0.169, 95%CI 0.092 to 0.247). In our cohort, we observed 10.5% of tested NP specimens had detectable SARS-CoV-2. Based on the observed impact of NP specimen quality, we estimate that the reduction of quality NP specimen collection that results in β-actin Ct increasing from 28 to 32 (roughly 25% to 75% percentile) decreases the absolute probability of SARS-CoV-2 detection by 5.4% (95%Cl 2.7% to 8.2%). This finding has several important implications. First, the correlation between β-actin Ct and SARS-CoV-2 suggests that quantitative interpretation of SARS-CoV-2 human specimens may be enhanced by adjusting for the β-actin Ct. Second, the data support the concern that poor specimen collection may contribute to false-negative results. The concern of false-negative NP SARS-CoV-2 testing has led to the recommendation to retest patients with moderate to high clinical suspicion of COVID-19 (29, 30). Reporting the β-actin Ct, or a β-actin-adjusted SARS-CoV-2 Ct may allow clinicians to better interpret specimen quality when considering retesting. We considered the possibility that the observed relationship between SARS-CoV-2 and β-actin Ct values might be confounded by respiratory disease severity, but we found no significant association between independent markers of severe respiratory disease and lower β-actin Ct values. However, several limitations of our analysis must be acknowledged. Oxygen saturation data and chest CT radiography reports were only available for a small percentage (32.6% and 8.5%, respectively) of our subjects. Subject demographics and medical comorbidities could not be ascertained for subjects, so unmeasured confounders may contribute to the observed association. Nevertheless, we believe that the observed association between NP specimen quality and SARS-CoV-2 RT-PCR sensitivity is an important finding. From 1311 NP specimens submitted for SARS-CoV-2 testing, we have quantified the variation in specimen quality measured by βactin Ct value, and we have defined the impact of the observed variation on test sensitivity and SARS-CoV-2 Ct values.

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

SARS-CoV-2 Ct values have shown promise as a means to roughly quantify viral burden and so to guide infection control and public health interventions (1, 2, 4-8). However, variability in NP specimen collection may exert large effects on observed SARS-CoV-2 Ct values, limiting these useful applications. As testing efforts expand, infrastructure to ensure quality sample collection must expand as well (9). Concurrent measurement of a β-actin human gene target may provide a means to recognize and adjust for variability in NP specimen quality. Figures: Figure 1: Distribution and relationships of Ct values for SARS-CoV-2, β-actin, and MS2 DNA positive control. A matrix plot depicting the observed cycle of threshold values for SARS-CoV-2 RT-PCR, with MS2 DNA positive control and β-actin specimen quality control over 1311 consecutive clinical assays run between March 26 and July 4, 2020. Panels on the diagonal present the distribution of each target's Ct values. Panels off the diagonal present the relationship between Ct values for each pair of targets. Ct for specimens without detectable SARS-CoV-2 or β-actin were imputed at 40 cycles.

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

Figure 2: Relationship between β-actin and SARS-CoV-2 detection probability. Binomial logistic regression relating SARS-CoV-2 detection to β-actin Ct value reveals a negative association, with high β-actin Ct (i.e., low quality) NP specimens less likely to detect SARS-CoV-2. The absolute probability of SARS-CoV-2 detection is presented in relation to the observed range of β -actin Ct values. **REFERENCES** 1. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y, Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM. 2020. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nature medicine 26:672-675. 2. Singanayagam A. Patel M. Charlett A. Lopez Bernal J. Saliba V. Ellis J. Ladhani S. Zambon M, Gopal R. 2020. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, england, january to may 2020. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 25.

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

3. Westblade LF, Brar G, Pinheiro LC, Paidoussis D, Rajan M, Martin P, Goyal P, Sepulveda JL, Zhang L, George G, Liu D, Whittier S, Plate M, Small CB, Rand JH, Cushing MM, Walsh TJ, Cooke J, Safford MM, Loda M, Satlin MJ. 2020. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer cell 38:661-671.e2. 4. Rhee C, Kanjilal S, Baker M, Klompas M. 2020. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity: When is it safe to discontinue isolation? Clinical infectious diseases: an official publication of the Infectious Diseases Society of America https://doi.org/10.1093/cid/ciaa1249. 5. Tom MR, Mina MJ. 2020. To interpret the SARS-CoV-2 test, consider the cycle threshold value. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 71:2252–2254. 6. Alteri C, Cento V, Vecchi M, Colagrossi L, Fanti D, Vismara C, Puoti M, Perno CF, SCOVA Study Group. 2020. Nasopharyngeal SARS-CoV-2 load at hospital admission as predictor of mortality. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America https://doi.org/10.1093/cid/ciaa956. 7. Binnicker MJ. 2020. Challenges and controversies to testing for COVID-19. Journal of clinical microbiology 58. 8. Hay JA, Kennedy-Shaffer L, Kanjilal S, Lipsitch M, Mina MJ. 2020. Estimating epidemiologic dynamics from single cross-sectional viral load distributions, medrxiv;2020.10.08.20204222v1. Epidemiology. medRxiv. 9. Procop GW, Shrestha NK, Vogel S, Van Sickle K, Harrington S, Rhoads DD, Rubin BP, Terpeluk P. 2020. A direct comparison of enhanced saliva to nasopharyngeal swab for the

detection of SARS-CoV-2 in symptomatic patients. Journal of clinical microbiology 58.

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

10. Sethuraman N, Jeremiah SS, Ryo A. 2020. Interpreting diagnostic tests for SARS-CoV-2. JAMA: the journal of the American Medical Association 323:2249–2251. 11. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, Ji W. 2020. Sensitivity of chest CT for COVID-19: Comparison to RT-PCR. Radiology 296:E115-E117. 12. Higgins TS, Wu AW, Ting JY. 2020. SARS-CoV-2 nasopharyngeal swab Testing-False-Negative results from a pervasive anatomical misconception. JAMA otolaryngology- head & neck surgery https://doi.org/10.1001/jamaoto.2020.2946. 13. Smieja M, Castriciano S, Carruthers S, So G, Chong S, Luinstra K, Mahony JB, Petrich A, Chernesky M. Savarese M. Triva D. 2010. Development and evaluation of a flocked nasal midturbinate swab for self-collection in respiratory virus infection diagnostic testing. Journal of clinical microbiology 48:3340-3342. 14. CDC. 2020. Discontinuation of Transmission-Based precautions and disposition of patients with COVID-19 in healthcare settings (interim guidance). https://www.cdc.gov/coronavirus/2019ncov/hcp/disposition-hospitalized-patients.html. 15. LeBlanc JJ, Gubbay JB, Li Y, Needle R, Arneson SR, Marcino D, Charest H, Desnoyers G, Dust K, Fattouh R, Garceau R, German G, Hatchette TF, Kozak RA, Krajden M, Kuschak T, Lang ALS, Levett P, Mazzulli T, McDonald R, Mubareka S, Prystajecky N, Rutherford C, Smieja M, Yu Y, Zahariadis G, Zelyas N, Bastien N, COVID-19 Pandemic Diagnostics Investigation Team of the Canadian Public Health Laboratory Network (CPHLN) Respiratory Virus Working Group. 2020. Real-time PCR-based SARS-CoV-2 detection in canadian laboratories. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 128:104433.

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

edition. CRC Press/Taylor & Francis Group.

16. Vermeiren C, Marchand-Senécal X, Sheldrake E, Bulir D, Smieja M, Chong S, Forbes JD, Katz K. 2020. Comparison of copan ESwab and FLOQSwab for COVID-19 diagnosis: Working around a supply shortage. Journal of clinical microbiology 58. 17. Rolfe KJ, Parmar S, Mururi D, Wreghitt TG, Jalal H, Zhang H, Curran MD. 2007. An internally controlled, one-step, real-time RT-PCR assay for norovirus detection and genogrouping. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 39:318–321. 18. Bas A, Forsberg G, Hammarström S, Hammarström M-L. 2004. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scandinavian journal of immunology 59:566-573. 19. R Core Team. 2018. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 20. Wickham H. 2016. Ggplot2: Elegant graphics for data analysis1st ed. 2009. Corr. 3rd printing 2010 edition. Springer International Publishing. 21. Carpenter B, Gelman A, Hoffman M, Lee D, Goodrich B, Betancourt M, Brubaker M, Guo J, Li P, Riddell A. 2017. Stan: A probabilistic programming language. Journal of statistical software 76:1–32. 22. Bürkner P-C. 2017. Brms: An R package for bayesian multilevel models using stan. Journal of Statistical Software, Articles 80:1–28. 23. McElreath R. 2016. Statistical rethinking: A bayesian course with examples in R and stan1

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

24. Gabry J, Simpson D, Vehtari A, Betancourt M, Gelman A. 2019. Visualization in bayesian workflow. Journal of the Royal Statistical Society Series A, 182:389–402. 25. Gelman A, Vehtari A, Simpson D, Margossian CC, Carpenter B, Yao Y, Kennedy L, Gabry J, Bürkner P-C, Modrák M. 2020. Bayesian workflow. 26. Rothman KJ, Greenland S. 2018. Planning study size based on precision rather than power. Epidemiology 29:599-603. 27. Gelman A, Tuerlinckx F. 2000. Type S error rates for classical and bayesian single and multiple comparison procedures. Computational statistics 15:373–390. 28. Gelman A, Carlin J. 2014. Beyond power calculations: Assessing type S (sign) and type M (magnitude) errors. Perspectives on psychological science: a journal of the Association for Psychological Science 9:641–651. 29. Gniazdowski V, Morris CP, Wohl S, Mehoke T, Ramakrishnan S, Thielen P, Powell H, Smith B, Armstrong DT, Herrera M, Reifsnyder C, Sevdali M, Carroll KC, Pekosz A, Mostafa HH. 2020. Repeat COVID-19 molecular testing: Correlation of SARS-CoV-2 culture with molecular assays and cycle thresholds. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America https://doi.org/10.1093/cid/ciaa1616. 30. Hanson KE, Caliendo AM, Arias CA, Englund JA, Lee MJ, Loeb M, Patel R, El Alayli A, Kalot' MA, Falck-Ytter Y, Lavergne V, Morgan RL, Hassan Murad M, Sultan S, Bhimraj A, Mustafa RA. 2020. Infectious diseases society of america guidelines on the diagnosis of COVID-19.



